Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risperidone: how good is the evidence for efficacy?

J A Mattes1

  • 1Psychopharmacology Research Association of Princeton, NJ 08540, USA.

Schizophrenia Bulletin
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.

Archives of general psychiatry·2000
Same author

Mood improvement from transcranial magnetic stimulation.

The American journal of psychiatry·1999
Same author

Fluoxetine and norfluoxetine.

The American journal of psychiatry·1998
Same author

Sertindole versus haloperidol for schizophrenia.

The American journal of psychiatry·1998
Same author

Stroke resulting from a rapid switch from phenelzine to tranylcypromine.

The Journal of clinical psychiatry·1998
Same author

Olanzapine on trial.

The American journal of psychiatry·1998
Same journal

Reconsidering the Term "Treatment Resistant Schizophrenia".

Schizophrenia bulletin·2026
Same journal

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026
Same journal

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Schizophrenia bulletin·2026
Same journal

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.

Schizophrenia bulletin·2026
Same journal

Longitudinal Impact of Birthweight and its Polygenic Risk Score on Glucose and Antipsychotic-Induced Weight Gain in First Episode Psychosis.

Schizophrenia bulletin·2026
See all related articles

This review examines risperidone

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Trials

Background:

  • Risperidone is an atypical antipsychotic medication.
  • Its efficacy compared to traditional antipsychotics requires thorough evaluation.

Purpose of the Study:

  • To review published literature on risperidone's efficacy.
  • To assess its effectiveness against haloperidol and placebo.

Main Methods:

  • Systematic review of multicenter, double-blind studies.
  • Comparison of risperidone with haloperidol and placebo.
  • Analysis of risperidone versus standard neuroleptics.

Main Results:

  • Risperidone shows efficacy, particularly in refractory patients.

Related Experiment Videos

  • Potential artifactual superiority in negative symptoms due to extrapyramidal symptoms.
  • Possible antidepressant effects noted for risperidone.

    • Conclusions:

    • Risperidone's efficacy is reported, but study populations were often treatment-resistant.
    • Further research is needed to confirm risperidone's effectiveness for positive symptoms in responsive patients.